F3 Antibody - #DF6400
(6)
(2)
製品説明
ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
反応性:
Human,Mouse
クローナリティ:
Polyclonal
特異性:
F3 Antibody detects endogenous levels of total F3.
RRID:
AB_2838363
引用形式: Affinity Biosciences Cat# DF6400, RRID:AB_2838363.
引用形式: Affinity Biosciences Cat# DF6400, RRID:AB_2838363.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:
折りたたみ／展開
CD142; CD142 antigen; Coagulation factor III (thromboplastin tissue factor); Coagulation factor III; F3; FLJ17960; TF; TF_HUMAN; TFA; Thromboplastin; Tissue factor;
免疫原
免疫原:
A synthesized peptide derived from human F3, corresponding to a region within C-terminal amino acids.
Uniprot:
遺伝子(ID):
発現特異性:
タンパク質の説明:
This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010]
タンパク質配列:
- P13726 TF_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
METPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVECMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS
研究背景
機能:
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.
細胞の位置付け:
Membrane>Single-pass type I membrane protein.
Secreted.
組織特異性:
Lung, placenta and pancreas.
タンパク質ファミリー:
Belongs to the tissue factor family.
研究領域
· Organismal Systems > Immune system > Complement and coagulation cascades. (View pathway)
参考文献
1). Multifunctional Co-Delivery Systems with Downregulation of the Novel Target PIM1 in Macrophages to Ameliorate TF-Mediated Coagulopathy in Sepsis. Small (Weinheim an der Bergstrasse, Germany), 2025
(PubMed: 40135385)
[IF=13.0]
Application: WB Species: Mouse Sample: lung tissue
Figure 3 PIM1 inhibitor SMI-4a protects septic mice against coagulation activation and sepsis-induced acute lung injury. A) Schematic representation of animal experimental procedures. B) Representative western blot membranes and corresponding densitometric analyses of (C) PIM1 in lung tissue (n = 6/group). D) mRNA levels of PIM1 in murine lung tissues (n = 5/group). E) Platelet count in mice (n = 4/group). F–H) Plasma levels of coagulation-related factors in mice plasma by ELISA, including (F) TAT, (G) D-dimer, and (H) fibrinogen (n = 4/group). I) The lung sections were subjected to hematoxylin and eosin (HE) staining, F4/80, fibrin, and PIM1 immunohistochemical analysis (n = 4/group; scale bar:50 µm). J) Representative western blot membranes and corresponding densitometric analyses of (K) TF, (L) PAI-1, (M) Thrombin in lung tissue (n = 6/group). N) mRNA levels of TF in murine lung tissues (n = 5/group). O–Q) mRNA levels of (O) IL-1β, (P) IL-6, and (Q) TNF-ɑ in murine lung tissues (n = 5/group). R) Survival curves of mice in all groups (n = 10/group). Each bar represents the mean ± SD. Statistical analysis for three or more groups was carried out using one-way ANOVA (C-H and K-Q).
2). TREM2 improves coagulopathy and lung inflammation in sepsis through the AKT-mTOR pathway. International immunopharmacology, 2025
(PubMed: 39970715)
[IF=4.8]
3). Piperlongumin Improves Survival in the Mouse Model of Sepsis: Effect on Coagulation Factors and Lung Inflammation. INFLAMMATION, 2022
(PubMed: 35831643)
[IF=4.5]
Application: WB Species: Mouse Sample: RAW264.7 cells
Fig. 6 PL reduces the surge in TF and PAI-1 in macrophages stimulated by LPS. A, B Each group was tested using qRT-PCR to detect TF and PAI-1 mRNA levels. C ELISA determined concentrations of PAI-1 in the supernatant of the RAW264.7 cell. D, E Western blot analysis showed protein levels of TF in RAW264.7 cells. F–I AKT, mTOR, and STAT3 phosphorylation was detected by western blot in RAW264.7 cells. Every experiment was repeated three times. Values are indicated as mean ± SD. **P
4). Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway. Journal of Inflammation Research, 2023
(PubMed: 36926276)
[IF=4.5]
5). Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. VASCULAR PHARMACOLOGY, 2021
(PubMed: 33232770)
[IF=3.5]
6). Fibroblast growth factor 2 (FGF2) ameliorates the coagulation abnormalities in sepsis. Toxicology and applied pharmacology, 2023
(PubMed: 36621722)
[IF=3.3]
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.